Exicure, Inc. - Investor Relations (exicuretx.com)
Exicure, Inc. - Investor Relations
Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure's proprietary 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential
investors.exicuretx.com
Exicure, Inc. (Nasdaq:XCUR) (exicuretx.com)
Exicure, Inc. (Nasdaq:XCUR)
Our Science Our SNA technology enables delivery of genetically-targeted therapies to a broad range of tissues and cells. We have shown potential application in preclinical studies in the CNS, eye, lung and the GI tract. Learn more about how our SNA technol
www.exicuretx.com
2020_11_12_Corporate_Presentation.pdf
3.36MB
10 Q quarterly report.pdf
0.77MB
728x90
'---매수대상--- > 미국 스몰캡 주당 10불 이하' 카테고리의 다른 글
| GLMD GALMED PHARMACEUTICALS 갈메드 (0) | 2021.01.29 |
|---|---|
| ADMA (0) | 2021.01.29 |
| LIFE ATVR PHARMA (0) | 2021.01.29 |
| ATPO 압토즈 바이오 (0) | 2020.12.11 |
| PROG 여성 치료 전용 바이오 (0) | 2020.12.10 |
댓글